European Union grants orphan drug designation to LSK BioPharma Apatinib

Release Date: 13-Apr-2017

LSK BioPharma, a leading biopharmaceutical company announced that company’s novel small-molecule angiogenesis inhibitor, Apatinib is awarded with orphan drug designation from European Commission for the effective treatment of gastric cancer.
EMA orphan designation is intended to encourage development of medicines for the diagnosis, treatment, or prevention of life-threatening or chronically debilitating conditions that affect no more than 5 in 10,000 people in the EU. Medicines that receive orphan designation are eligible for a number of incentives, including assistance with development of the medicine; reduced fees for marketing-authorization applications; and extended market exclusivity once the medicine is authorized. Orphan designation is conferred following a positive opinion by the EMA's Committee for Orphan Medicinal Products (COMP).
“Global Orphan Drug Clinical Pipeline Insight” reports by kuick research gives comprehensive insight on various clinical and non-clinical aspects associated with ongoing clinical trials of 808 orphan designated drugs across the globe. The in-depth clinical insight presented in the report helps the reader to analyze and identify the various stakeholders involved in the clinical development and commercialization of orphan designated drugs in the global market. Currently there are more than 300 orphan designated drugs commercially available in the global market and around 800 drugs in clinical development phase.
For Orphan Drug Clinical Insight Reports Contact:          

Need custom market research solution? We can help you with that too.